Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF wild-type melanoma progressing on prior anti-programmed death-1 therapy.

Eur J Cancer

Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address:

Published: January 2023